Josh Morrison argues that AI superforecasting could transform FDA drug approval by replacing subjective expert judgment with objective, quantitative predictions about drug safety and efficacy.

Scott Alexander examines how compounding pharmacies are producing cheaper versions of GLP-1 agonist drugs, exploring the economics, safety, and future implications of this practice.

Scott Alexander examines the complexities of abolishing the FDA and proposes more practical alternatives to increase medical innovation while maintaining safeguards.

Scott Alexander responds to comments on his post about new telemedicine regulations, addressing various concerns and criticisms raised by readers.

Scott Alexander criticizes new DEA regulations that restrict telemedicine prescriptions for controlled substances, arguing they will harm patients and legitimate practices while failing to prevent abuse.

Scott provides updates on efforts to get FDA approval for fluvoxamine as a COVID-19 treatment and reports on the early approval of Paxlovid.

Scott Alexander argues that the EpiPen price hike is due to over-regulation and cronyism in the pharmaceutical industry, not lack of regulation as suggested by Vox.

Scott Alexander presents a satirical list of fictional drugs banned by the FDA, each with an absurd reason for its prohibition.